Manila Times Business
Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor "What This Means” Segment
- Access the segment here HOUSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor "What This Means” segment. As part of the segment, Mr. Klemp discussed the Company’s recent news announcing that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in combination with cytarabin
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
ZEELOOL Launches French Summer Edit for Summer 2026
Just now
When water leadership fails
Just now
Concierra Legal Releases New Guide on What a Prenuptial Agreement Can Actually Do for Founders, Executives, and High-Net-Worth Individuals in Texas
Just now
Moving Beyond the Binder: ChairPulse Debuts AI-Powered Operations Layer for Dental Practices
Just now